GlassScriptPhysician profile
Lisa O Cabrera
NPI 1811962723
$12,277.67
in general payments reported to CMS, 2019-2025
37 companies · $2,590 in 2025
The $2,590 reported for 2025 was more than what 91% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $908 · 2020: $410 · 2021: $1,771 · 2022: $1,673 · 2023: $2,275 · 2024: $2,650 · 2025: $2,590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,204 · Consulting Fee: $270 · Education: $41.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,203.52 |
| Consulting Fee | $270.00 |
| Education | $41.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,486.28 | 2019-2025 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $1,274.49 | 2019-2025 | Velphoro, Velphoro |
| Opko Pharmaceuticals, LLC | $1,015.44 | 2019-2025 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $818.05 | 2021-2025 | |
| Amgen INC. | $655.34 | 2019-2025 | Krystexxa, Tavneos |
| Medtronic, INC. | $568.25 | 2022-2024 | Ellipsys Vascular Access System |
| Glaxosmithkline, LLC. | $500.77 | 2021-2025 | Benlysta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $410.45 | 2023-2025 | Jardiance |
| Daiichi Sankyo INC. | $397.57 | 2019-2025 | Injectafer |
| Lilly USA, LLC | $362.61 | 2021-2025 | Mounjaro, Jardiance |
| Novo Nordisk INC | $346.18 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $333.84 | 2019-2023 | Jynarque |
| Aurinia Pharma U.S., INC. | $319.35 | 2021-2024 | Lupkynis |
| Travere Therapeutics, INC. | $299.08 | 2022-2025 | |
| Calliditas Therapeutics US INC. | $284.20 | 2022-2025 | Tarpeyo |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA INC. | $250.00 | 2021 | |
| Horizon Therapeutics Plc | $246.12 | 2019-2023 | Krystexxa |
| Ardelyx, INC. | $219.00 | 2023-2025 | Ibsrela |
| Vifor Pharma, INC. | $204.12 | 2020-2023 | Veltassa, Korsuva |
| Akebia Therapeutics INC | $163.34 | 2019-2024 | Vafseo |
| Venturemed Group, INC. | $152.87 | 2024 | Flex Vessel Prep System |
| Nxstage Medical, INC. | $151.15 | 2022-2023 | Nxstage System One |
| Mallinckrodt Hospital Products INC. | $142.36 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $109.59 | 2021-2025 | |
| Ani Pharmaceuticals, INC. | $105.16 | 2023-2025 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $80.96 | 2022-2023 | Soliris |
| Merck Sharp & Dohme LLC | $79.33 | 2024 | Verquvo |
| Kyowa Kirin, INC. | $67.41 | 2023-2025 | Crysvita |
| Allergan, INC. | $41.40 | 2020 | |
| Cormedix INC. | $41.07 | 2024 | Defencath |
| Scpharmaceuticals INC. | $36.45 | 2025 | |
| Tactile Systems Technology INC | $33.71 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $19.80 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $17.45 | 2022 | |
| Boston Scientific Corporation | $17.12 | 2023 | Lux-Dx Insertable Cardiac Monitor |
| Mannkind Corporation | $14.67 | 2025 | |
| Arbor Pharmaceuticals, INC. | $12.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Cabrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.